Lipoprotein(a) [Lp(a)]

Your standard lipid panel measures LDL cholesterol. It doesn’t measure Lp(a). Yet elevated Lp(a) affects roughly one in five people worldwide and substantially increases risk of heart attack, stroke, and aortic valve disease. Unlike LDL cholesterol, Lp(a) levels are almost entirely determined by your genes. Diet, exercise, and most medications barely move it.

Decades of genetic and epidemiological research confirm that Lp(a) is a causal risk factor for cardiovascular disease. Mendelian randomization studies show that people born with genetic variants for lower Lp(a) have proportionally lower rates of coronary artery disease, peripheral artery disease, and calcific aortic stenosis. The risk is continuous, with no clear safe threshold.

Yet most people have never had their Lp(a) measured. Most doctors don’t order it routinely. And until recently, no approved therapies existed to lower it substantially.

The landscape is changing. New RNA-targeted therapies can reduce Lp(a) by 80% or more. Large outcomes trials are underway. Guidelines increasingly recommend measuring Lp(a) at least once in every adult. The articles below provide a comprehensive guide for understanding this overlooked risk factor and making informed decisions about testing, monitoring, and management.

Lp(a) Articles

What Is Lp(a)? Learn what Lp(a) is, how it differs from LDL, why it evolved, and why it poses both lipid and thrombotic risks. Understand the genetics behind this unique lipoprotein.
Lp(a) and Your Risk Quantify what elevated Lp(a) means in absolute and relative terms. Learn how Lp(a) interacts with other risk factors and what natural history to expect.
Unanswered Scientific Questions Explore what remains uncertain about causality, isoforms, plaque regression, and long-term effects of Lp(a) lowering.
How to Test Lp(a) Get practical details on testing: mass versus molar units, isoform-insensitive assays, when to retest, and what additional tests might be useful.
Current Lp(a) Treatments Understand what existing therapies can and cannot do. Explore statins, PCSK9 inhibitors, niacin, lipoprotein apheresis, and aspirin for high Lp(a) patients.
Emerging Lp(a) Therapies Discover the pipeline of antisense oligonucleotides and siRNA therapies that may transform Lp(a) management. Track key trials and realistic approval timelines.
Lifestyle and Lp(a) Honest assessment of what diet, supplements, and exercise can realistically achieve for Lp(a) levels. Understand hormonal influences and what doesn’t work.
Integrating Lp(a) Into Your Regimen How Lp(a) management fits with statins, PCSK9 inhibitors, and other cardiovascular medications. Understand drug interactions, monitoring adjustments, and therapeutic goals.
Navigating Lp(a) Care Find the right specialists, coordinate between providers, and advocate effectively for appropriate testing and treatment within your healthcare system.
Lp(a) Clinical Trials Learn how to find and evaluate trials, weigh the pros and cons of participation, and understand what happens when trials end.
Lp(a) Insurance and Economics Navigate coverage for testing and treatment. Understand the economic forces shaping Lp(a) care and how to prepare for new therapies.
Lp(a) Market and Industry Landscape Explore the pharmaceutical pipeline, diagnostic market, guideline evolution, and patient advocacy organizations shaping Lp(a) care.
Legal and Regulatory Considerations Understand the evolving standard of care, FDA approval pathways, and how drug labeling affects treatment access.
Lp(a) and Your Family Cascade screening, genetic counseling, and how to discuss inherited cardiovascular risk with children and relatives.
Staying Informed on Lp(a) Key journals, researchers, conferences, patient resources, and how to track pipeline developments without getting lost in hype.